ScreenerHero

LSTALisata Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · lisata.com
1.550USD+38.39%Mkt Cap: 13.97M $P/E: —

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational prod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap13.97M $
Enterprise Value-604.75K $
Revenue (TTM)100.00K $
Gross Profit100.00K $
Net Income (TTM)-16.59M $
Revenue/Share0.0110 USD
Last Price1.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.97
PEG118.40
EV/EBITDA0.04
EV/Revenue-6.05
P/S100.92
P/B1.24
EPS (TTM)-1.64
EPS (Forward)-1.16
52W Range
0.987514% of range5.070
52W High5.070 USD
52W Low0.9875 USD
Profitability
Gross Margin100.00%
Oper. Margin-16426.00%
EBITDA Margin0.00%
Profit Margin-9756.47%
ROE-111.65%
ROA-93.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.95M $
CapEx (TTM)28.00K $
FCF Margin-8100.25%
FCF Yield-58.00%
Net Debt-10.44M $
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity0.00
Current Ratio3.69
Quick Ratio3.56
Book Value/Sh0.9040 USD
Cash/Share1.159 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateSep 15, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.01M
Float7.11M
Insiders21.11%
Institutions12.03%
Short Interest
Short Ratio0.5d
Short % Float0.75%
Short % Out.0.62%
Shares Short56.34K
Short (prev mo.)104.81K
Technical
SMA 502.458 (-36.9%)
SMA 2003.158 (-50.9%)
Beta0.88
S&P 52W Chg18.16%
Avg Vol (30d)341.16K
Avg Vol (10d)66.07K
Technical Indicators
RSI (14)46.0
MACD-0.3784
MACD Signal-0.4790
MACD Hist.+0.1005
BB Upper1.771 USD
BB Middle1.219 USD
BB Lower0.6666 USD
BB Width90.63%
ATR (14)0.2027 USD
Vol Ratio (20d)68.04x